(118 days)
No
The summary describes a standard electrosurgical unit using radiofrequency energy for tissue coagulation and hemostasis. There is no mention of AI, ML, image processing, or any data-driven algorithms for decision-making or analysis. The device operation is described as being through an "intuitive user interface," which does not imply AI/ML capabilities.
Yes.
The device is intended for the percutaneous treatment of facial wrinkles in Skin Types I-V, which is a therapeutic purpose.
No
The device is intended for electrocoagulation and hemostasis in dermatologic and general surgical procedures, and for the percutaneous treatment of facial wrinkles. These are therapeutic, not diagnostic, uses.
No
The device description explicitly lists hardware components such as a device console, handpieces, RF plate, foot switch, and power cord, indicating it is not software-only.
Based on the provided information, the VYBE RF II is not an In Vitro Diagnostic (IVD) device.
Here's why:
- Intended Use: The intended use is for "dermatologic and general surgical procedures for electrocoagulation and hemostasis," and for the "percutaneous treatment of facial wrinkles." These are procedures performed directly on the human body, not on samples taken from the body.
- Device Description: The device delivers "high-frequency energy to the human body through the needle tip cartridge." This describes a device that interacts directly with living tissue.
- Lack of IVD Characteristics: There is no mention of analyzing samples (blood, urine, tissue, etc.) or providing diagnostic information based on such analysis. The device's function is therapeutic (coagulation, hemostasis, wrinkle treatment) through the application of energy.
IVD devices are used to examine specimens derived from the human body to provide information for diagnostic, monitoring, or compatibility purposes. The VYBE RF II does not fit this description.
N/A
Intended Use / Indications for Use
The VYBE RF II is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Microneedle Array Handpiece (1MHz): The Microneedle Array Handpiece with 1 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. At power less than 36W, the Microneedle Array Handpiece with 1 MHz functionality is intended for the percutaneous treatment of facial winkles in Skin Types I-V.
Microneedle Array Handpiece (2MHz): The Microneedle Array Handpiece with 2 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The Microneedle Array handpiece with 2MHz functionality is not intended to treat wrinkles.
One Pin Exact Handpiece: The One Pin Exact handpiece with 1MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The One Pin Exact Handpiece is not intended to treat wrinkles.
Product codes
GEI
Device Description
VYBE RF II is a High Frequency Electrosurgical Unit that uses electrical currents to coagulate tissue. The device consists of the device console, Microneedle Array Handpiece, One Pin Exact Handpiece, RF plate, Foot Switch, and Power Cord. VYBE RF II is operated through an intuitive user interface (UI) on a 10.4- inch wide touch LCD screen. This product delivers high-frequency energy to the human body through the needle tip cartridge connected to the Microneedle Array Handpiece (1MHz, 2MHz) and One Pin Exact Handpiece (1MHz).
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
Facial (for wrinkles), dermatologic and general surgical procedures.
Indicated Patient Age Range
Not Found
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Performance Testing:
-Bench testing was performed to verify the accuracy of the output of RF energy.
-Histopathology testing was conducted to demonstrate the thermal effect of the device.
Histopathology Testing Summary:
In vitro testing of the VYBE RF II Radiofrequency Microneedling device (Test Device), equipped with VYBE RF Microneedle Array handpiece (HP) and SH-TIP cartridges, and operated at 1 and 2 MHz frequencies was performed. Testing was performed on three different types of tissue recommended by the FDA: ex vivo kidney (bovine), and skin (Yucatan mini-pig, abdomen site). "FDA guidance for Industry for Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery" recommends conducting testing at minimum, medium (default), and maximum (highest) power settings. The Test Device can be operated at two different frequencies 1- and 2 MHz. It is also operated at power levels from 1 to 10 with level 1 as the minimum and 10 maximum (highest) power level for both frequencies. Therefore, testing was performed at levels 1, 5, and 10 for both frequencies with the longs pulse width available on the device to demonstrate a 'worst case.'
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Verification and validation activities were successfully completed and establish that the Vybe RF II performs as intended. Testing included:
- IEC 60601-1:2005 + A1:2012; Medical Electrical Equipment- Part 1: General Requirements For Basic Safety And Essential Performance
- IEC 60601-1-2:2014; Medical Electrical Equipment- Part 1-2: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Electromagnetic Disturbances - Requirements And Tests
- IEC 60601-2-2:2017; Medical Electrical Equipment -part 2-2: Particular Requirements For The Basic Safety And Essential Performance Of High Frequency Surgical Equipment And High Frequency Surgical Accessories
- IEC 62304:2006+A1:2015; Medical Device Software Life Cycle Processes
- EN ISO 14971:2012; Medical Devices Application Of Risk Management To Medical Devices
- IEC 60601-1-6:2010, AMD1:2013, AMD2:2020- Medical Electrical Equipment Part 1-6: General requirements for safety- collateral standard: Usability
Software verification and validation testing was conducted, and documentation provided in accordance with FDA's Guidance or the Content of Premarket Submissions for Software Contained in Medical Devices.
Bench testing was performed to verify the accuracy of the output of RF energy. Histopathology testing was conducted to demonstrate the thermal effect of the device.
Histopathology testing demonstrated the ability of the Test Device to achieve consistent thermal damage profiles in line with the target treatment. It can be concluded that treatment by such a device at the appropriate settings will possess a desirable clinical treatment effect.
No clinical studies were conducted as part of this submission.
Patient contacting materials have been determined to be biocompatible.
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 878.4400 Electrosurgical cutting and coagulation device and accessories.
(a)
Identification. An electrosurgical cutting and coagulation device and accessories is a device intended to remove tissue and control bleeding by use of high-frequency electrical current.(b)
Classification. Class II.
0
Image /page/0/Picture/0 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). The logo consists of two parts: the Department of Health & Human Services logo on the left and the FDA logo on the right. The FDA logo features the letters "FDA" in a blue square, followed by the words "U.S. FOOD & DRUG ADMINISTRATION" in blue text.
September 25, 2024
ShenB Co. Ltd. % Aubrey Thompson Regulatory Consultant Hoy & Associates Regulatory Consultants 1830 Bonnie Way Sacramento, California 95825
Re: K241535
Trade/Device Name: Vybe RF II Regulation Number: 21 CFR 878.4400 Regulation Name: Electrosurgical Cutting And Coagulation Device And Accessories Regulatory Class: Class II Product Code: GEI Dated: August 27, 2024 Received: August 27, 2024
Dear Aubrey Thompson:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrb/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rule"). The UDI Rule requires, among other things, that a device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE(@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
2
Sincerely,
Digitally signed by Long H. Chen Long H. Chen-S 3 Date: 2024.09.25 07:42:48 -04'00'
Long Chen, Ph.D. Assistant Director DHT4A: Division of General Surgery Devices OHT4: Office of Surgical and Infection Control Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
510(k) Number (if known) K241535
Device Name VYBE RF II
Indications for Use (Describe)
The VYBE RF II is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Microneedle Array Handpiece (1MHz): The Microneedle Array Handpiece with 1 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. At power less than 36W, the Microneedle Array Handpiece with 1 MHz functionality is intended for the percutaneous treatment of facial winkles in Skin Types I-V.
Microneedle Array Handpiece (2MHz): The Microneedle Array Handpiece with 2 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The Microneedle Array handpiece with 2MHz functionality is not intended to treat wrinkles.
One Pin Exact Handpiece: The One Pin Exact handpiece with 1MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The One Pin Exact Handpiece is not intended to treat wrinkles.
Type of Use (Select one or both, as applicable)
| Prescription Use (Part 21 CFR 801 Subpart D) | Over-The-Counter Use (21 CFR 801 Subpart C) |
|---|---|
| --------------------------------------------------------------------------------------------------------------- | -------------------------------------------------------------------------------------------------------------- |
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
510(K) Summary Vybe RF II System K241535
| Applicant
Address | ShenB Co., Ltd.
Shenb Bldg 148, Seongsui-ro
Seongdong-Gu, Seoul, 04796
Republic of Korea |
|-----------------------------------------|---------------------------------------------------------------------------------------------------|
| Contact Person | Aubrey Thompson, Regulatory Consultant |
| Contact Information
Preparation Date | aubreythompson@hoyregulatory.com
September 24, 2024 |
| Device Trade Name | Vybe RF II |
| Classification Name | Electrosurgical Cutting and Coagulation Device and
Accessories |
| Regulation Number | 878.4400 |
| Product Code | GEI |
| Regulatory Class | II |
| Legally Marketed Predicate Devices | Virtue RF (K211562)
Vybe RF (K230986) |
Device Description:
VYBE RF II is a High Frequency Electrosurgical Unit that uses electrical currents to coagulate tissue. The device consists of the device console, Microneedle Array Handpiece, One Pin Exact Handpiece, RF plate, Foot Switch, and Power Cord. VYBE RF II is operated through an intuitive user interface (UI) on a 10.4- inch wide touch LCD screen. This product delivers high-frequency energy to the human body through the needle tip cartridge connected to the Microneedle Array Handpiece (1MHz, 2MHz) and One Pin Exact Handpiece (1MHz).
Indications for use:
The VYBE RF II is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Microneedle Array Handpiece:
Microneedle Array Handpiece (1MHz): The Microneedle Array Handpiece with 1 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. At power less than 36W, the Microneedle Array Handpiece with 1 MHz functionality is intended for the percutaneous treatment of facial wrinkles in Skin Types I-V.
Microneedle Array (2MHz): The Microneedle Array Handpiece with 2 MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The Microneedle Array handpiece with 2MHz functionality is not intended to treat wrinkles.
One Pin Exact Handpiece: The One Pin Exact handpiece with 1MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The One Pin Exact Handpiece is not intended to treat wrinkles.
5
510(K) Summary
Vybe RF II System
Substantial Equivalence—Indications for use and Technical Compariso
| Specification | Vybe RF II (Subject Device) | Virtue RF (K211562) | Vybe RF (K230986) | Comparison |
|---|---|---|---|---|
| Product Code Operation | GEI | |||
| Radiofrequency Microneedling | GEI | |||
| Radiofrequency Microneedling | GEI | |||
| Radiofrequency Microneedling | Same | |||
| # of needles | 36 needle tip, 1 needle tip | 36, 12, and 1 needle tips | 36 needle tip | The 36 and 1 needle tips are identical to those used in the Virtue RF. The 12 needle tip in the Virtue RF is not included in Vybe RF II. The reference device, K230986, includes only a 36 needle tip. |
| Frequency | 2MHz, 1MHz | 2MHz, 1MHz, 0.5Mhz | 2MHz, 1MHz | The 0.5 MHz frequency of the Virtue RF corresponds to the 12 needle tip and is not included in Vybe RF II. |
| Modality | Monopolar and Bipolar | Monopolar and Bipolar | Bipolar | Same as predicate. Reference device contains only bipolar. |
| Indications | The VYBE RF II is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. |
Microneedle Array Handpiece (1MHz): The Microneedle Array | The Virtue RF System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis.
Smart RF Handpiece: The Smart RF Handpiece with 1 MHz functionality is intended for use in | The VYBE RF Electrosurgical System is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis and the percutaneous treatment facial wrinkles for use with Fitzpatrick Skin Type I to Skin Type Vwhen using the | Same. The Virtue RF includes additional indications for the Deep RF handpiece, which is not included in this submission. The indications for use for the subject device specifies the power level under which the wrinkles indication is allowable. |
6
510(K) Summary
Vybe RF II System
| Handpiece with 1
MHz functionality is
intended for use in
dermatologic and
general surgical
procedures for
electrocoagulation
and hemostasis. At
power less than 36W,
the Microneedle Array
Handpiece with 1
MHz functionality is
intended for the
percutaneous
treatment of facial | dermatologic and general
surgical procedures for
electrocoagulation and
hemostasis, and the
percutaneous treatment of
facial wrinkles. The
VirtueRF System for facial
wrinkles is intended for use
with Skin types I-V. The
Smart RF Handpiece with 2
MHz functionality is
intended for use in
dermatologic and general
surgical procedures for
electrocoagulation and
hemostasis. The Smart RF
with 2MHz functionality is
not intended to treat
wrinkles. | 1MHz setting. The 2MHz
setting has not been
evaluated for use in the
percutaneous treatment of
facial wrinkles and is
intended for use in
dermatologic and general
surgical procedures for
electrocoagulation and
hemostasis. |
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| wrinkles in Skin Types
I-V.
Microneedle Array
(2MHz): The
Microneedle Array
Handpiece with 2
MHz functionality is
intended for use in
dermatologic and
general surgical
procedures for
electrocoagulation
and hemostasis. The
Microneedle Array
handpiece with 2MHz
functionality is not
intended to treat
wrinkles. | Exact RF Handpiece: The
Exact RF Handpiece with
1MHz functionality is
intended for use in
dermatologic and general
surgical procedures for
electrocoagulation and
hemostasis. The Exact RF
Handpiece is not intended
to treat wrinkles. | |
7
Page 4 of 7
| K241535 | One Pin Exact Handpiece: The One Pin Exact handpiece with 1MHz functionality is intended for use in dermatologic and general surgical procedures for electrocoagulation and hemostasis. The One Pin Exact Handpiece is not intended to treat wrinkles. | |
|---|---|---|
| --------- | -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- | -- |
| Specification | Subject Device – VYBE RF II
Microneedle Array
HANDPIECE (SH-TIP) | Predicate Device - Virtue RF
SMART RF HANDPIECE | Reference Device –
VYBE RF | Comparison |
|----------------------|------------------------------------------------------------------------|----------------------------------------------------|---------------------------------------|----------------------------------------------------------------------------------------------------------------------------|
| Modality | Bipolar fractional RF | Bipolar fractional RF | Bipolar fractional RF | Same |
| Radiofrequency | 1MHz, 2MHz | 1MHz, 2MHz | 1MHz, 2MHz | Same |
| Electrode Type | Bipolar microneedle | Bipolar microneedle | Bipolar microneedle | Same |
| Number of
needles | 36 | 36 | 36 | Same |
| Max power | 59 W @ 1 MHz
30 W @ 2MHz | 35.9 W @ 1 MHz
25 W @ 2MHz | 59W | Different. The max
power output is higher
for the subject device
than for the predicate.
See discussion below. |
| RF Duration | 100ms-800ms, with 100ms
increments | 100ms-800ms, with 100ms
increments | 100ms-800ms, with
100ms increments | Same |
8
510(K) Summary
Vybe RF II System
| Same |
|---|
| Max 3.5mm depth |
| Microneedle length |
| Microneedle spacing |
| Microneedle density |
| Specification | Subject Device – VYBE RF II ONE PIN EXACT HANDPIECE | Predicate Device - Virtue RF EXACT RF HANDPIECE | Reference Device - VYBE RF | Comparison |
|---|---|---|---|---|
| Modality | Monopolar Fractional RF | Monopolar Fractional RF | N/A | Same |
| Radiofrequency | 1 MHz | 1 MHz | N/A | Same |
| Electrode Type | Monopolar single needle RF electrode | Monopolar single needle RF electrode | N/A | Same |
| Number of needles | 1 | 1 | N/A | Same |
| Max power | 46 W | 46 W | N/A | Same |
| RF Duration | 100ms-800ms, with 100ms increments | 100ms-800ms, with 100ms increments | N/A | Same |
| Grounding Mechanism | Disposable Neutral electrode pad | Neutral electrode plate | N/A | Different. The grounding mechanism is the same, the materials and reuse are different. |
9
510(K) Summary Vybe RF II System K241535
Performance Testing
Verification and validation activities were successfully completed and establish that the Vybe RF II performs as intended. Testing included the following:
- . IEC 60601-1:2005 + A1:2012; Medical Electrical Equipment- Part 1: General Requirements For Basic Safety And Essential Performance
- IEC 60601-1-2:2014; Medical Electrical Equipment- Part 1-2: General Requirements For Basic Safety And Essential Performance - Collateral Standard: Electromagnetic Disturbances - Requirements And Tests
- . IEC 60601-2-2:2017; Medical Electrical Equipment -part 2-2: Particular Requirements For The Basic Safety And Essential Performance Of High Frequency Surgical Equipment And High Frequency Surgical Accessories
- IEC 62304:2006+A1:2015; Medical Device Software Life Cycle Processes ●
- EN ISO 14971:2012; Medical Devices Application Of Risk Management To Medical ● Devices
- IEC 60601-1-6:2010, AMD1:2013, AMD2:2020- Medical Electrical Equipment Part 1-6: General requirements for safety- collateral standard: Usability
Software verification and validation testing was conducted, and documentation provided in accordance with FDA's Guidance or the Content of Premarket Submissions for Software Contained in Medical Devices.
Bench testing was performed to verify the accuracy of the output of RF energy. Histopathology testing was conducted to demonstrate the thermal effect of the device. A test summary is provided below.
Histopathology Testing Summary
In vitro testing of the VYBE RF II Radiofrequency Microneedling device (Test Device), equipped with VYBE RF Microneedle Array handpiece (HP) and SH-TIP cartridges, and operated at 1 and 2 MHz frequencies was performed. Testing was performed on three different types of tissue recommended by the FDA: ex vivo kidney (bovine), and skin (Yucatan mini-pig, abdomen site). "FDA guidance for Industry for Premarket Notification (510(k)) Submissions for Electrosurgical Devices for General Surgery" recommends conducting testing at minimum, medium (default), and maximum (highest) power settings. The Test Device can be operated at two different frequencies 1- and 2 MHz. It is also operated at power levels from 1 to 10 with level 1 as the minimum and 10 maximum (highest) power level for both frequencies. Therefore, testing was performed at levels 1, 5, and 10 for both frequencies with the longs pulse width available on the device to demonstrate a 'worst case.'
The study demonstrated the ability of the Test Device to achieve consistent thermal damage profiles in line with the target treatment. Thus, it can be concluded that treatment by such a device at the appropriate testings will possess a desirable clinical treatment effect.
Clinical Evidence - N/A. No clinical studies were conducted as part of this submission.
Biocompatibility – Patient contacting materials have been determined to be biocompatible.
10
510(K) Summary Vybe RF II System K241535
Discussion
The VYBE RF II shares the same indications for use, technological characteristics, and handpieces as the Predicate device, the Virtue RF System. The main difference between the two devices is the maximum power achieved with the 36 needle handpiece and disposable tip. The Vybe RF II has a higher maximum power while using the same 36 needle tip, but the same power level as the reference device (the previously cleared Vybe RF). The single needle tip is identical to the predicate device except for the type of neutral electrode used. Thermal testing, biocompatibility testing, essential performance testing, and IEC testing demonstrate the VYBE RF II is safe and effective and can be considered substantially equivalent to the predicate device.